Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin

Despite improvements in treatment regimens for osteosarcoma (OS) patients, survival rate has not increased over the last two decades. New treatment modalities are therefore warranted. Preclinical results with conditionally replicative adenoviruses (CRAds) to treat OS are promising. One type of CRAd...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Graat, H C A, Witlox, M A, Schagen, F H E, Kaspers, G J L, Helder, M N, Bras, J, Schaap, G R, Gerritsen, W R, Wuisman, P I J M, van Beusechem, V W
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2006
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361338/
https://ncbi.nlm.nih.gov/pubmed/16736005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603189
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky